FDA delivered on a promise for quick review of new products that “address critical national health priorities” this week. The agency granted approval for Wegovy HD – a 7.2 mg high-dose regimen for semaglutide in obesity. The “priority” rationale can be whatever you like, depending on your perspective.

So Much Winning

For Novo Nordisk, it’s a priority to catch up with Lilly, which has been trouncing them with Mounjaro in this fiercely  competitive market. Patients and clinicians will like having more flexibility in dosing this drug – especially for those who reach a plateau in outcomes with lower doses.

For FDA, it meets a need to claim an easy win under a new “Commissioner’s National Priority Voucher” program. After all, approving an incremental dosing regimen for a wildly popular obesity medicine presents a pretty low risk while offering bragging rights. “The new FDA is moving with unprecedented efficiency on products that advance national priorities,” said FDA Commissioner Martin Makary.

Dosing Flexibility

From our perspective, the real win in this case is the dosing flexibility for an important drug. This is especially important because obesity is such a heterogeneous condition. Different people respond very differently to treatment. Some respond better to one drug than they might to another. Clinical trials show that some will respond to this higher dose of semaglutide better than they did to lower doses. Everyone has different clinical needs and this gives clinicians and patients a bit more flexibility to tailor therapy to those needs. On social media, obesity medicine physician Michael Albert summed up the value of this approval:

“For our patients who have plateaued on 2.4 mg, or who came in with higher baseline BMI and greater metabolic burden, this opens a legitimate clinical conversation about dose escalation. This isn’t about chasing a number. It’s about getting people to durable, meaningful weight reduction – and increasingly, the data shows higher doses get more people there.”

Incremental steps toward better obesity care might not be flashy, but they certainly matter. This approval is a case in point.

Click here and here for the pivotal clinical trials with Wegovy HD. For more on this approval, click here, here, and here.

Study of Steps, painting by Giovanni Segantini / WikiArt